How could preventive therapy affect the prevalence of drug resistance? Causes and consequences by Kunkel, A et al.
rstb.royalsocietypublishing.orgResearch
Cite this article: Kunkel A, Colijn C, Lipsitch
M, Cohen T. 2015 How could preventive
therapy affect the prevalence of drug
resistance? Causes and consequences. Phil.
Trans. R. Soc. B 370: 20140306.
http://dx.doi.org/10.1098/rstb.2014.0306
Accepted: 19 February 2015
One contribution of 9 to a theme issue
‘Antimicrobial resistance: addressing the threat
to global health’.
Subject Areas:
health and disease and epidemiology
Keywords:
prophylaxis, preventive, mathematical model,
antibiotic resistance, indirect effects,
competition
Author for correspondence:
Amber Kunkel
e-mail: agkunkel@gmail.com& 2015 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
License http://creativecommons.org/licenses/by/4.0/, which permits unrestricted use, provided the original
author and source are credited.Electronic supplementary material is available
at http://dx.doi.org/10.1098/rstb.2014.0306 or
via http://rstb.royalsocietypublishing.org.How could preventive therapy affect the
prevalence of drug resistance? Causes and
consequences
Amber Kunkel1,3, Caroline Colijn2, Marc Lipsitch1 and Ted Cohen3
1Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA
2Department of Mathematics, Imperial College, London SW7 2AZ, UK
3Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT 06520, USA
Various forms of preventive and prophylactic antimicrobial therapies have been
proposed to combat HIV (e.g. pre-exposure prophylaxis), tuberculosis (e.g. iso-
niazid preventive therapy) and malaria (e.g. intermittent preventive treatment).
However, the potential population-level effects of preventative therapy (PT) on
the prevalence of drug resistance are not well understood. PT can directly affect
the rate at which resistance is acquired among those receiving PT. It can also
indirectly affect resistance by altering the rate at which resistance is acquired
through treatment for active disease and by modifying the level of competition
between transmission of drug-resistant and drug-sensitive pathogens. We pro-
pose a general mathematical model to explore the ways in which PT can affect
the long-term prevalence of drug resistance. Depending on the relative contri-
butions of these three mechanisms, we find that increasing the level of
coverage of PT may result in increases, decreases or non-monotonic changes in
the overall prevalenceofdrug resistance. These results demonstrate the complex-
ity of the relationship between PT and drug resistance in the population. Care
should be taken when predicting population-level changes in drug resistance
from small pilot studies of PT or estimates based solely on its direct effects.1. Introduction
Preventive and prophylactic infectious disease therapies (wewill refer to both col-
lectively as preventive therapy, PT) involve the use of chemotherapeutic agents in
asymptomatic and non-infectious individuals, with the goal of preventing future
symptoms and infectiousness. PT may be applied to individuals who are either
uninfected or latently infected with a given pathogen. For example, whereas iso-
niazid preventive therapy for tuberculosis (TB) can prevent disease progression in
latently infected individuals [1,2], pre-exposure prophylaxis for human immuno-
deficiency virus (HIV) is intended solely for use in uninfected individuals [3].
Some interventions may include aspects of both treatment and PT; for example,
intermittent preventive treatment formalaria involves a full course of antimalarial
treatment applied irrespective of infection status [4].
Because PT prevents development of infectiousness as well as symptoms,
PT has been proposed as an element of public health strategies aimed at redu-
cing the burden of TB, HIV and malaria [4–6]. However, such strategies have
often been controversial, with concerns about drug resistance forming one
major barrier to implementation [7,8]. When the chemotherapeutic agents
that are used for prevention are also needed for treatment, any drug resistance
produced or amplified as a result of PT may undermine future control efforts.
Simulation models intended to assess the potential effects of PT on the preva-
lence of drug resistance have produced sometimes inconsistent results [9]. For
example, Supervie et al. [10,11] predicted that rolling out pre-exposure prophy-
laxis in Botswana would reduce the prevalence of drug-resistant (DR) HIV,
whereas Abbas et al. [12,13] predicted that a similar programme in South
Africa would increase the prevalence of DR HIV.
Table 1. Model states and parameters.
state name description (all states: proportion of population)
S susceptible uninfected, negative infection history
LS DS latent latently infected with DS strain
LR DR latent latently infected with DR strain
IS DS actively infected infectious with DS strain, not on treatment
IR DR actively infected infectious with DR strain, not on treatment
TS DS treated infectious with DS strain, on treatment
TR DR treated infectious with DR strain, on treatment
IS* total DS infectious sum of DS infectious states: IS þ IPTS þ TS
IR* total DR infectious sum of DR infectious states: IR þ IPTR þ TR
R recovered uninfected, positive infection history
parameter name description
bS DS transmission parameter # DS effective contacts per susceptible per unit time
bR DR transmission parameter # DR effective contacts per susceptible per unit time
kS DS progression rate rate of progression from DS latent to DS actively infected
kR DR progression rate rate of progression from DR latent to DR actively infected
c case detection rate rate at which actively infected individuals begin treatment
rS DS recovery rate rate of recovery from DS treated to recovered
rR DR recovery rate rate of recovery from DR treated to recovered
a treated resistance rate rate resistance is acquired due to treatment
al PT latent resistance rate rate resistance is acquired by DS latents on PT
ai PT active resistance rate rate resistance is acquired by DS actively infecteds on PT
x reinfection susceptibility susceptibility retained after initial infection
w PT exit rate reciprocal of average duration of PT
f PT uninfected start rate start rate of PT for uninfected individuals
fl PT latent start rate start rate of PT for latently infected individuals
fi PT active start rate start rate of PT for actively infected individuals
superscript name description
PT preventive therapy state/parameter refers to individuals receiving PT
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2Models intended to predict the effects of specific PT
programmes tend to be fairly complex, with states and par-
ameters chosen to reflect the natural history of the disease of
interest, the operational details of the proposed intervention
and the efficacy of the available drug. While this complexity
may improve the predictive accuracy of each individual
model, it can complicate attempts to explain differences in
their predictions [9,11,13]. In this paper, we create a simplified,
general model of PT with the goal of better understanding the
ways in which PT could alter the population prevalence of
drug resistance. We show that increasing PT coverage can
have qualitatively different effects on the prevalence of drug
resistance depending on the relative importance of resistance
acquired as a result of PT, resistance acquired as a result of
treatment and the competitive fitness of DR strains.2. Material and methods
We developed a simple mathematical model to demonstrate the
ways in which PT may alter the prevalence of drug resistance.
Mathematical modelling provides a way to formally encode
our understanding of the individual-level effects of PT, some ofwhich may lead to drug resistance. Furthermore, mathematical
modelling creates a conceptual framework to explore how the
effects of PT on drug resistance in the population may extend
beyond its immediate recipients.(a) Model structure: disease course
A description of the states and parameters used in our model is
given in table 1. Figure 1 displays the structure of this compart-
mental model, with the health states and transitions among
individuals not receiving PT on the left-hand side (a) and
among individuals receiving PT on the right-hand side (b). We
focus first on individuals not receiving PT (figure 1a). Although
this portion of the figure shows the rates at which individuals
may begin and end PT (PT states shown in dotted boxes), it
does not display transitions between PT states.
Within the model, an individual may be infected by pathogen
phenotypes that are either drug sensitive (DS, indicated in the dia-
gram by a subscript S) or DR (indicated in the diagram by a
subscript R), but not by both simultaneously. Not allowing for
mixed infections greatly simplifies our model, but introduces
strong assumptions about competition between strains, the impli-
cations of which are considered in the Discussion. Susceptible (S)
persons who are infected enter latency with either the DS strain
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Figure 1. (a) All states and transitions involving individuals not on PT (solid boxes), with transitions on and off PT shown via links to on-PT states (dashed boxes).
(b) All states and transitions involving individuals on PT (solid boxes), with transitions off and on PT shown via links to off-PT states (dashed boxes).
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3(LS) or the DR strain (LR), depending on the source of the infection.
Latently infected individuals may be superinfected and move to
the latent state characterized by the drug sensitivity pattern of the
most recently infecting strain. We assume the degree of suscepti-
bility to reinfection x does not depend on the identity of the
initial or reinfecting strain. We do allow the risks of infection
and progression to active disease to differ based on the drug sensi-
tivity of the infecting strain, reflecting the potential fitness costs
of resistance.
All actively infected individuals within our model, including
those on treatment, contribute to the overall force of infection.
We assume that infectious individuals cannot be reinfected and
cannot recover except by treatment. We allow individuals receiv-
ing treatment for DS disease to acquire resistance at rate a. We
assume such acquired resistant cases are immediately detected
and started on treatment for DR disease, which we assume has a
lower cure rate than treatment for DS disease. We do not allow
for disease-inducedmortality or explicitly encode for treatment fail-
ure, though the latter may be incorporated into the treatment cure
rate. Once cured, individuals revert to a recovered (R) state exhibit-
ing the same level of immunity as that experienced by latently
infected individuals.
Though we omit arrows representing mortality from figure 1,
we assume a constant mortality rate from each compartment and
a constant population size. All individuals enter the model sus-
ceptible to infection and not on PT. Because we assume a fixed
population size, we express all states in terms of proportion of
the population.
(b) Model structure: preventive therapy
Figure 1b displays the portion of our model pertaining to individ-
uals receiving PT. This portion of the figure again displays the rates
at which individuals may begin or end PT (non-PT states shown indotted boxes), but omits arrows indicating the transitions between
states of individuals not receiving PT. We allow for individuals
who are uninfected, latently infected or actively infected to poten-
tially receive PT. Uninfected individuals begin PT at rate f and
cease therapy at rate w. Latently infected individuals begin PT at
rate fl and cease therapyat ratew. We allow the rates at which unin-
fected and latently infected individuals initiate PT to differ, as the
specific targeting of PT depends on the disease and drug of inter-
est. Pre-exposure prophylaxis for HIV, for example, is intended
solely for uninfected individuals [3], whereas isoniazid preventive
therapy is typically targeted to individuals with latent TB infection
[1,2]. We assume that the PT initiation rate is the same for both DS
and DR latently infected individuals, assuming that the resistance
phenotype of the infecting strain is not known during latency.
Actively infected individuals may also receive PT within our
model. Though PT is generally not intended for such individuals
(except when the same drug is applied as both treatment and pre-
vention, e.g. intermittent preventive treatment for malaria [4]),
individuals may progress from latent to active infection while
receiving PT (rate kPTS ) or initiate PT during active disease as a
result of imperfect screening (rate fi). We assume that the PT start
rate is the same for both DS and DR actively infected individuals,
assuming the infection is not recognized prior to PT initiation. We
assume that actively infected individuals cease PT routinely, at rate
w, or upon initiation of treatment, at the same case detection rate c
as for individuals not receiving PT.
The health states for individuals receiving PT are similar to
those described for individuals not receiving PT. We assume
PT reduces the rate at which uninfected and latently infected
individuals are infected with the DS strain (bPTS , bS), the rate
at which DS latently infected individuals progress to active dis-
ease (kPTS , kS), or the rates of both infection and progression
with the DS strain. Although we assume that PT has no direct
effect on infection or progression with the DR strain, it may
RPT
LS LR
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PT IR
PT
kSPT
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Figure 2. Subset of the model representing the rates at which individuals
with latent or active DS disease receiving PT (LPTS and I
PT
S , respectively) acquire
resistance (bold) and the transitions leading to these potentially at-risk states.
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4affect the probability of progression with the DR strain by chan-
ging the probability of reinfection with the DS strain. We allow
DS latently infected individuals to acquire resistance as a result
of PT at rate al and DS actively infected individuals at rate ai.
We assume PT does not cure or reduce the infectiousness of indi-
viduals with active infection. We also assume that individuals
cannot receive PT and treatment simultaneously, but treated
individuals again become eligible for PT upon recovery.
Throughout our analysis, we do not track which individuals
receive PT and thus assume that the same individuals may
receive multiple courses of PT.
(c) Outcome measures
Throughout our analysis, we focus on the equilibrium behaviour
of the model. Doing so simplifies our analysis by removing its
dependence on the initial model conditions. We begin each
of our analyses in the absence of PT (setting the PT start rates
f ¼ fl ¼ fi ¼ 0). For each of our analyses, we choose a parameter
set such that, in the absence of PT, the equilibrium prevalence
of the DS strain is non-zero and the basic reproductive number
of the DR strain exceeds 1. Because we allow for acquired resist-
ance, the former requirement implies that the equilibrium
prevalence of the DR strain is also non-zero in the absence of
PT (i.e. there is no DS only equilibrium). The latter implies that
the equilibrium prevalence of the DR strain will remain non-
zero even if the equilibrium prevalence of the DS strain does not.
Holding this parameter set fixed, including the rates of case
detection and treatment for active disease, we run a series of simu-
lations at progressively higher values of the PT initiation rate. For
the purpose of our simulations, we assume the PT start rates
among uninfected, latently infected and infectious individuals are
proportional throughout, with fl ¼ f and fi ¼ f/10, and thus refer
to the PT start rate using the single parameter f. For each individual
simulation, we fix the value of the PT initiation rate, run the model
to equilibrium (i.e. until changes in population composition
between time steps become negligible), and record the resulting
prevalence of the DR strain. We repeat the simulation process for
incrementally increasing values of f until the DS strain is eliminated
(the equilibrium prevalence of the DS strain equals 0), still holding
the PT initiation rate constant within each individual simulation.
Because we do not allow DR strains to revert to DS, such elimin-
ation of the DS strain is possible in our model even when the
equilibrium prevalence of the DR strain remains non-zero.
All of the results provided are based on model simulations
created using the R differential equation solver ‘ode’ within
package deSolve.3. Results
In our model, increasing the intensity of PT directly affects the
amount of resistance acquired through PT. It also indirectly
affects the amount of resistance acquired through treatment
for active disease and the competitive transmission advantage
afforded to DR strains. We find that the combined effects of
these mechanisms can result in increasing, decreasing, and
non-monotonic relationships between the intensity of PT cov-
erage and DR prevalence. Throughout the results, we use the
word ‘treatment’ to refer solely to treatment for active disease.
(a) Preventive therapy coverage and resistance acquired
through preventive therapy
In our model, PT may lead directly to acquired resistance
among individuals latently or actively infected with the DS
strain. To demonstrate how it may do so, figure 2 providesa focused view of the relevant states and transitions from
figure 1. Unbolded arrows in figure 2 show the transitions
that may lead to individuals latently or actively infected
with the DS strain receiving PT. Bolded arrows show the
acquisition of resistance among such individuals as a result
of PT. If no individuals are to acquire resistance as a result
of PT, one of the following scenarios must apply: (i) no indi-
viduals with active or latent infection ever receive PT, (ii) no
individuals with active infection ever receive PT, and PT
never results in acquired resistance among latently infected
individuals or (iii) PT never results in acquired resistance
among latently or actively infected individuals. The first scen-
ario assumes that PT is intended only for uninfected
individuals, that screening for latent and active infection
prior to PT initiation is perfect ( fi ¼ 0 and fl ¼ 0) and that
adherence and drug efficacy are sufficiently high that indi-
viduals receiving PT never become infected (bPTS ¼ 0). The
second scenario assumes that PT never selects for sporadi-
cally occurring resistant mutants among individuals with
latent infection (al ¼ 0), that screening for active infection
prior to PT initiation is perfect ( fi ¼ 0), and that adherence
and drug efficacy are sufficiently high that individuals receiv-
ing PT never progress from latent to active infection (kPTS ¼ 0).
The third scenario assumes that PT is incapable of selecting for
resistance at the individual level among both latently and
actively infected individuals (al ¼ 0 and ai ¼ 0). Even well-
functioning PT programmes are unlikely to meet these strin-
gent criteria, and thus it is reasonable to expect that some
individuals will directly acquire resistance as a result of PT.
When we assume that some or all of these parameters are
non-zero, reflecting the vast majority of real-world PT appli-
cations, the relationship between PT coverage and resistance
acquired as a result of PT is shown in figure 3. The level of
resistance acquired through PT is a function of the number
of DS actively and latently infected individuals receiving PT
(aiIPTS þ alLPTS ). When PT coverage is low and insufficiently
able to control the epidemic, increasing PT coverage increases
the number of latently and actively infected individuals
receiving PT and thus the number of people who acquire
resistance as a result of PT. When PT coverage is high and
better able to control the epidemic, increasing PT coverage
decreases the number of people who acquire resistance as a
result of PT (similar to an effect described in [14]). Under
such scenarios, although increasing the PT initiation rate
still increases the total number of people receiving PT, the
resulting reduction in the force of DS infection is sufficient
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Figure 3. The relationship between PT start rate f and the rate at which resist-
ance is acquired through PT (ai IPTS þ alLPTS ) at equilibrium. Parameters for
this figure: m ¼ 0.02, rR ¼ 1, rS ¼ 2, c ¼ 1, kR ¼ 1, kS ¼ 1.5, bS ¼ 2,
bR ¼ 1, x ¼ 1, a ¼ 0.3, ai ¼ 0.5, al ¼ 0.1, w ¼ 0.1, bPTS ¼ 0, kPTS ¼ 0.
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Figure 4. The relationship between PT start rate f and the rate at which
resistance is acquired through treatment for DS disease (aTS) at equilibrium.
Parameters for this figure are the same as those for figure 3.
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5to decrease the number of people receiving PT who have
latent or active DS infection. Because only DS infected indi-
viduals are at risk of acquiring resistance as a result of PT,
this results in a reduction of the rate at which resistance is
acquired as a result of PT.
(b) Preventive therapy coverage and resistance acquired
through treatment
As shown in figure 1, our model allows individuals receiving
treatment for active DS disease (TS) to acquire resistance at
rate a. Increasing the coverage of PT in the population decreases
the number of people infected with the DS strain, and thus
decreases the number of peoplewho acquire resistance through
treatment for active disease. This relationship is shown in
figure 4.
(c) Preventive therapy coverage and transmission
of the drug-resistant strain
Our model assumes high levels of competition for susceptible
hosts between strains, as we do not allow for latent or active co-
infection. As a result, increasing PT coverage may provide a
selective advantage toDR strains through twodistinctmechan-
isms. First, increasing PT coverage increases the probability
that an individual latently infected with the DR strain will
progress to active DR infection. This relationship is a result of
our assumption that DR latently infected individuals could
potentially be ‘rescued’ from progressing to DR disease by
superinfection with the DS strain. As PT coverage increases,
DR latently infected individuals are increasingly protected
from such superinfection and are therefore more likely to pro-
gress with their DR strain. Second, increasing PT coverage
increases the proportion of DR uninfected individuals who
are susceptible to the DR strain. In our model, the proportion
of all individuals who are susceptible to the DR strain is
given by S þ xLS þ xR þ SPT þ xLSPT þ xRPT, which
depends on the proportion of people uninfected by the DR
strain, the proportion of people with active DS infection, and
the level of immunity afforded by initial infection. To obtainthe proportion of DR uninfected individuals who are suscep-
tible to DR infection, we divide this by the total proportion
of individuals not actively or latently infected with the DR
strain (S þ R þ LS þ SPT þ RPT þ LSPT þ IS þ ISPT þ
TS). Increasing PT coverage reduces the number of persons
with active DS infection, and therefore increases the propor-
tion of DR uninfected individuals who are susceptible to the
DR strain. These two effects are discussed in more detail in
the electronic supplementary material.
The effective reproductive number of the DR strain is a
compositemeasure that allows us to assess the combined effects
of these mechanisms on the competitive fitness of the DR
strain. The effective reproductive number shows the number
of secondary infectious cases produced by a single infectious
individual over the course of their infectious period. As
opposed to the basic reproductive number R0, which assumes
a wholly susceptible population, the effective reproductive
number at a given time point depends on the susceptibility pat-
tern of the population at that point in time. In a single strain
model, the effective reproductive number at equilibrium is
equal to 1. In our model, however, the number of DR infected
individuals is boosted by acquired resistance, and therefore
the DR strain may coexist with the DS strain in the population
even when the effective reproductive number of the DR strain
is below 1.
Figure 5 shows how the effective reproductive number of
the DR strain at equilibrium changes as PT coverage increases.
At low PT coverage levels, the DR effective reproductive
number is less than 1, indicating that acquired resistance is
necessary for the persistence of the DR strain in the population.
As PT coverage increases, the reproductive fitness of the DR
strain increases as well. When PT coverage is sufficiently
high, the DR effective reproductive number reaches 1, indicat-
ing that resistance has become self-sustaining and theDR strain
has overtaken the DS strain in the population.(d) Composite effects of preventive therapy coverage
on drug-resistant prevalence
Table 2 summarizes the ways in which each of the resistance
mechanisms outlined above will tend to alter DR prevalence.
While increasing PT coverage can decrease the rate of
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Figure 5. The relationship between PT start rate f and the effective repro-
ductive number of the DR strain at equilibrium. Calculations are given in the
electronic supplementary material. Parameters for this figure are the same as
those for figure 3.
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6resistance acquired due to treatment, it can also increase the
competitive transmission advantage of circulating DR strains,
and its effects on the rate of resistance acquired due to PT are
non-monotonic. Furthermore, in our model as in reality, none
of these mechanisms exist in isolation. Rather, increasing PT
coverage acts simultaneously on the rate at which resistance
is acquired through PT, the rate at which resistance is
acquired through treatment, and the competitive fitness of
the DR strain. In figure 6, we show that the interactions
between these mechanisms are sufficient to produce a range
of qualitatively distinct relationships between PT coverage
and equilibrium DR prevalence. Though the behaviours
shown in this figure occur with varying frequencies and are
not necessarily exhaustive, they demonstrate the complexity
of the changes in DR prevalence that may result from PT.
Figure 6a–dwas created using the samemodel of PT under
different sets of parameters. The parameters used for each sub-
plot are shown in the figure caption. In figure 6a, DR
prevalence increasesmonotonicallywith PT coverage. The par-
ameters used to produce this subplot were the same as those
used to create the figures for the previous sections. In figure
6b, DR prevalence increases with PT coverage when PT cover-
age is low, but decreases with increasing PT coverage if PT
coverage exceeds a threshold value. To create this subplot,
we lowered the transmission parameter for the DR strain bR.
This decrease in the transmissibility of the DR strain allows
acquisition of resistance through PT and treatment to play a
larger role in changing DR prevalence. In figure 6c, DR preva-
lence decreases monotonically with increasing PT coverage. To
create this subplot, we lowered the transmission parameter of
the DR strain as in (b) and assumed that no resistance was
acquired as a result of PT, allowing acquisition of resistance
by treatment alone to become the major driver of DR preva-
lence. Finally, in figure 6d, DR prevalence decreases with
increasing PT coverage when PT coverage is low, but increases
with increasing PT coverage if PT coverage exceeds a threshold
value. To create this subplot, we lowered the reinfection sus-
ceptibility of latently infected and recovered individuals,
assumed no resistance acquired as a result of PT, and assumed
PT did not affect infection with the DS strain (i.e. that it onlyaffected disease progression). The resulting U-shaped curve
indicates that, at low coverage levels, PT primarily influences
resistance acquired due to treatment for active disease, whereas
at high coverage levels, PT exerts more influence by allowing
greater transmission of the DR strain. This relationship may
reflect the fact that lowering the progression rate affects the
prevalence of latent DS infection differently than the rate of
active DS infection, complicating the association between the
prevalence of DS disease and the number of people susceptible
to infection with the DR strain. Note that the absolute changes
in DR prevalence in this subplot are small; nevertheless, this
shape further reflects the complexity of the ways in which PT
may cause changes in DR prevalence.4. Discussion
Mathematical models of varying complexity have been con-
structed to predict the effects of pre-exposure prophylaxis for
HIV [10,12,15], isoniazid preventive therapy for TB [16–18]
and intermittent preventive treatment for malaria [19,20] on
the prevalence of drug resistance. Here, we have used a more
general model to provide an overall view of the ways in
which PT may influence the prevalence of drug resistance
and the anticipated directions of these effects.
First, we have described the relationship between PT cover-
age and the amount of resistance acquired directly as a result of
PT. Previousmodels have demonstrated particular sensitivity to
assumptions surrounding the use of PT in infected individuals
[21]. Ourmodel shows thatwhen PT coverage is low, increasing
PT coverage increases the amount of resistance acquired as a
result ofPT.WhenPTcoverage ishigh, however, further increas-
ingPTcoveragedecreases the amount of resistance acquiredas a
result ofPT, resulting inan invertedU-shaped curvebetweenPT
coverage and resistance acquired fromPT.A similar relationship
has been described between drug pressure and the rate of resist-
ance in the setting of treatment for active disease [14]. Notably,
this resistancemechanism is not a necessary consequence of the
beneficial effectsofPT. Thenumberofpeoplewhoacquire resist-
ance as a result of PTmay be reduced by limiting the number of
infected individuals started on PT (e.g. through better screening
programmes), the number of individuals receiving PT who
develop latent or active infection (e.g. through better adherence
or more effective PT drugs), and the rate at which infected indi-
viduals on PT acquire resistance (e.g. through drugs or drug
combinations more similar to those used for treatment).
Second, we have shown that increasing PT coverage
decreases the amount of resistance acquired as a result of treat-
ment for active disease. This relationship occurs because PT
decreases the number of individuals with active DS disease.
We would expect a similar relationship to hold for non-
therapeutic interventions that do not exclusively target DS
disease, such as condom use in the setting of HIV.
Third, we have demonstrated that increasing PT coverage
provides a selective advantage to circulating DR strains. We
have found that increasing PT coverage increases the effective
reproductive number of the DR strain, which is consistent
with predictions and observations for vaccines targeting
specific disease strains [22,23] and previous PT modelling
papers that have used strain competition to explain predicted
increases in DR prevalence [17,18]. Increasing the intensity of
PT coverage increases the effective reproductive number of
the DR strain by increasing the probability that a DR latently
Table 2. Summary of mechanisms through which PT may affect the prevalence of drug resistance. The proportion susceptible to the DR strain and the
reproductive number of the DR strain are discussed in more detail in the electronic supplementary material.
source of resistance
inﬂuence driven by effect on DR prevalence for
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Figure 6. Relationship between PT start rate f and DR prevalence (IR þ IPTR þ TR) at equilibrium. Parameters for (a) are the same as those from figures 3–5: m ¼
0.02, rR ¼ 1, rS ¼ 2, c ¼ 1, kR ¼ 1, kS ¼ 1.5, bS ¼ 2, bR ¼ 1, x ¼ 1, a ¼ 0.3, ai ¼ 0.5, al ¼ 0.1, w ¼ 0.1, bPTS ¼ 0, kPTS ¼ 0. Parameters for (b): same as
for (a), except bR ¼ 0.55. Parameters for (c): same as for (a), except bR ¼ 0.55, ai ¼ 0, al ¼ 0. Parameters for (d ): same as for (a), except x ¼ 0.4, ai ¼ 0,
al ¼ 0, bPTS ¼ 2. The same range of PT start rates is shown for each subplot, though this range is insufficient to cause elimination of the DS strain in (d ).
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7infected individual will progress to active DR infection
(before reinfection with the DS strain) and by increasing the
proportion of the DR uninfected population that is susceptible
to infection with the DR strain.
Finally, we have shown that PT may have a wide range of
effects on overall DR prevalence, depending on the interaction
of these three mechanisms. Specifically, we have provided
examples of increasing, decreasing, U-shaped and inverted
U-shaped relationships between PT intensity and equilibrium
DR prevalence resulting from our model. These four shapes
are not necessarily exhaustive, but demonstrate that the
relationship between PT coverage and DR prevalence may
differ qualitatively depending on the disease and drug in
question. In particular, predictions of the effects of PT on
drug resistance are sensitive to a number of properties of thesystem: the rate at which resistance is acquired as a result of
PT, the rate at which resistance is acquired as a result of treat-
ment, the fitness costs of resistance on disease transmissibility,
the mechanisms of PT and the rate of reinfection. Reliable esti-
mates of these parameters are needed to accurately predict
the effects of proposed PT programmes on DR prevalence.
Our estimates are also sensitive to the assumption that individ-
uals cannot be reinfected throughout their infectious periods,
illustrating the importance of understanding within-host
strain competition when predicting the population-level effects
of PT.
Understanding how each of these factors contribute to the
relationship between PT and drug resistance may aid in the
interpretation of models with differing predictions about
the effects of PT on drug resistance. For example, our analysis
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8sheds some additional light on the observations made by
Abbas et al. [13] on the sources of difference in the model pre-
dictions of Supervie et al. [10] and Abbas et al. [12]. Abbas et al.
[13] re-created both models to explore the reasons for contrast-
ing conclusions about the potential relationship between
pre-exposure prophylaxis (PrEP) and HIV drug resistance in
sub-Saharan Africa. They suggest that a low value of R0 contrib-
uted to PrEP decreasing the prevalence of drug resistance in
Supervie et al. [10], which accords with our demonstration that
although PT provides a competitive advantage to DR strains, it
may still reduce the overall prevalence of drug resistance when
the transmissibility of the DR strain is low and resistance is
driven primarily by acquisition. Similarly, their observation
that the differences between the two models could be partially
explained by differing PrEP coverage rates is supported by
our finding that the effects of increasing PT coverage may be
non-monotonic. The authors also acknowledge that resistance
in thepopulationoccurs as a resultof transmission and treatment
(i.e. antiretroviral therapy) as well as PrEP; as we have shown,
the effects of PT on drug resistance cannot be distilled to its
effects on resistance acquired through PT alone.
We have presented a general model that may not perfectly
reflect the natural history of any particular infection. Though in
reality the specific action and targeting of PT varies depending
on the disease and drug of interest, we assume PTprotects both
susceptible and latently infected individuals from active DS
disease. Our assumption of no latent or active mixed infections
encodes a high level of competition between strains for suscep-
tible hosts, the biological plausibility of which will depend on
the disease of interest. Other models have demonstrated that
allowing for mixed infections may either heighten or mitigate
the effective degree of competition between strains depending
on assumptions of how strains compete within and between
hosts [24–27]. If we could assume DS and DR strains are per-
fectly non-competing, changing PT coverage may not affect
the effective reproductive number of the DR strain; however,
we expect most pathogens to exhibit some level of competitionbetween strains and therefore qualitative behaviours similar to
those described here. In addition to the assumption of no
mixed infections, we assume a binary designation of drug
resistance that may not accurately represent the accumulation
of resistance mutations within a single host. Furthermore,
we do not allow DR strains to revert to DS, though this behav-
iour has been demonstrated for pathogens including HIV [28].
We assume that the effects of PT on disease progression cease
immediately after PT is removed, and do not allow PT to
increase the cure rate or reduce the infectiousness of infectious
individuals (as might occur if the drugs used for PT are similar
to those used for treatment). Similarly, we assume that PT
has no direct effects on immunity to future infection. Finally,
we focus our analysis on the effects of PT on drug resistance
at equilibrium, even though policy-makers may be most
interested in its short-term effects.
Nevertheless, we have provided a systematic account of
both direct and indirect mechanisms through which PT may
affect DR prevalence. Depending on the relative contributions
of these resistancemechanisms, raising PT coverage could have
increasing, decreasing or non-monotonic effects on long-term
DR prevalence. Because these relationships may be non-
monotonic, care should be takenwhen extrapolating the effects
of small PT programmes to larger efforts.
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